Summary of Twist Bioscience FY Conference Call Company Overview - **Company**: Twist Bioscience (NasdaqGS:TWST) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 03, 2026 Key Points Financial Performance and Strategy - Twist is on track to achieve adjusted EBITDA breakeven by Q4 of fiscal year 2026, with a focus on maximizing revenue growth while maintaining cost discipline [4][5] - The company has ramped revenue significantly, with 75%-80% of new revenue contributing to gross margin, improving from low 30s to over 50% [5][6] - The Total Addressable Market (TAM) has expanded from $2 billion in 2020 to $7 billion currently, with expectations to reach $12 billion by 2030 [7] AI and Therapeutics Segment - The therapeutic segment generated $111 million in revenue last year, growing over 25%, driven by AI capabilities in drug discovery [11] - Twist has developed automated high-throughput capabilities to meet the increasing demand for data from customers, particularly in the AI space [13][14] - The company emphasizes the importance of speed, throughput, and affordability in meeting customer needs, with a turnaround time of 17 days for data delivery, significantly faster than competitors [19][20] Market Dynamics and Competitive Advantage - Twist's competitive edge lies in its ability to provide high-quality data quickly and at scale, leveraging extreme automation and digital tracking [21][22] - The company is positioned to capitalize on the growing investment in AI by pharma and biotech companies, which are increasingly seeking efficient solutions for drug discovery [12][17] MRD (Minimal Residual Disease) Market - Twist is focusing on high sensitivity in cancer diagnostics, particularly in the MRD space, which saw over 200% growth last year [34] - The company offers a tumor-informed tool set with a significant number of probes at competitive pricing, enhancing sensitivity for MRD testing [33] - Expected revenue contribution from MRD is projected to be 1 to 2 percentage points of overall growth, with a ramp-up anticipated in the latter half of the year [36] Future Outlook - Twist aims to dominate the market, aspiring to achieve 100% market share in its segments [48] - The company is committed to continuous product innovation and commercialization efforts to expand its market presence [49] - The long-term growth strategy includes leveraging AI advancements and expanding the product portfolio to capture a larger share of the evolving market [48] Licensing and Partnerships - Twist announced a licensing deal with Invenra for bispecific technology, which is expected to facilitate AI-driven drug discovery [28][29] - The partnership aims to enhance Twist's capabilities in producing bispecific antibodies, which are challenging to manufacture at scale [29] Additional Insights - The company is focused on customer experience and repeat business, emphasizing the importance of delighting customers to foster loyalty and growth [24][25] - Twist is aware of the challenges in traditional drug discovery and aims to meet customers where they are, providing tailored solutions [26] This summary encapsulates the key insights from the Twist Bioscience conference call, highlighting the company's strategic direction, market opportunities, and competitive advantages in the biotechnology sector.